End of Enrollment for the Sore Throat Trial

The enrollment was completed for a phase IV, multicenter, randomized, non-inferiority trial by reaching the study-wide goal of including 360 patients. GCT is responsible for managing project in Russia where the patient enrolment began in August 2020.

From the start of the trial, Russian sites selected by GCT showed an encouraging recruitment rate resulting in the decision to open additional sites in the country. Initially, Russian sites were to recruit 156 out of 356 subjects in the study with the enrollment being competitive between 3 countries. While the recruitment in other countries dropped due to the global pandemic, GCT Russian team rescued the study by eventually enrolling 256 instead of 156 patients.  

“We are proud of the recruitment speed that the sites in Russia were able to achieve, despite the pandemic. Strategic partnerships between sponsors and CROs assuring the most effective patient enrollment approach is implemented, and the important milestones are achieved on time or beforehand,” said Jeffrey T. Apter, GCT President.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.